好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The MortalitY in Moderate-Severe TBI plus ICU-Complications (MYSTIC)-Score to Predict In-Hospital Mortality in Maximally Treated Moderate-Severe TBI Patients Including ICU Complications
Neuro Trauma, Critical Care, and Sports Neurology
S48 - Neurocritical Care: Traumatic Brain Injury and Goals-of-care Decision-making (1:24 PM-1:36 PM)
003

We developed and validated the parsimonious MortalitY in Moderate-Severe TBI plus ICU-Complications (MYSTIC)-Score to predict in-hospital mortality of maximally treated msTBI patients.

Current outcome models of moderate-severe traumatic brain injury (msTBI) include only admission characteristics, lacking adjustments for early deaths, limitations-of-care, or ICU complications.

We analyzed 485 msTBI patients consecutively enrolled in the single-center prospective observational OPTIMISM-study collecting 27 pre-defined ICU complications between 11/2009-5/2019. From that cohort, 2/3 were randomly selected for the MYSTIC-Score derivation and 1/3 for internal validation. Using multivariable logistic regression, we identified independent predictors of in-hospital mortality with validated admission predictors in maximally treated patients without early (<24h) death or limitations-of-care. Based on the model’s parameter estimates, we constructed the MYSTIC-Score and tested its discrimination and calibration in both cohorts using the area-under-the-receiver-operating-characteristic-curve(AUC) and Hosmer-Lemeshow-goodness-of-fit(HL) test.

In the derivation cohort (n=324), the mean age was 50 (SD=22) years, 72% were men, and 91% were non-Hispanic/Latino. In-hospital mortality was 36%. The MYSTIC-Score ranged from 34-189, with higher scores indicating higher likelihood of mortality, and included patient’s age, ethnicity, Marshall-CT-score, motor Glasgow-Coma-Scale, pupillary reactivity, pre-hospital hypotension, hypoxia, presence of traumatic SAH or epidural hematoma (all on admission), brain edema, herniation, Systemic-Inflammatory-Response-Syndrome, sepsis, acute kidney injury, cardiac arrest, and urinary tract infection (all in ICU). The score’s discrimination and calibration were excellent (AUC=0.95; HL-p-value=0.34, with p>0.05 indicating good calibration). In the validation cohort (n=161), ROC-AUC was 0.92 with a HL-p-value=0.01. The calibration curve indicated decreased calibration in the lowest decile of the MYSTIC-Score, likely due to limited power.

The MYSTIC-Score is the first tool to predict the risk of dying in the hospital in maximally treated msTBI patients including ICU complications. Our study highlights that adding ICU-complications to hospital admission criteria strengthens outcome prediction in msTBI. External validation is pending.

Authors/Disclosures
Michelle Chang, MS (1992)
PRESENTER
No disclosure on file
No disclosure on file
No disclosure on file
Marcey L. Osgood, DO No disclosure on file
Raphael A. Carandang, MD, FAAN (University of Massachusetts Medical School/UMASS Memorial Medical Group) Dr. Carandang has nothing to disclose.
Wiley Hall, MD (UMass Memorial Medical Center) No disclosure on file
No disclosure on file
Susanne Muehlschlegel, MD, MPH, FAAN (Johns Hopkins School of Medicine) Dr. Muehlschlegel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Acasti Pharma Inc.. Dr. Muehlschlegel has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acasti Pharma Inc.. The institution of Dr. Muehlschlegel has received research support from NIH. The institution of Dr. Muehlschlegel has received research support from NIH. The institution of an immediate family member of Dr. Muehlschlegel has received research support from NIH. The institution of Dr. Muehlschlegel has received research support from Johns Hopkins Stimulating and Advancing Anesthesiology & Critical Care Medicine Research (StAAR) Award. The institution of Dr. Muehlschlegel has received research support from Trustees of The Patrick and Catherine Weldon Donaghue Medical Research Foundation. The institution of Dr. Muehlschlegel has received research support from Harkin Family Fund (Johns Hopkins Dept. of Neurology). Dr. Muehlschlegel has received personal compensation in the range of $500-$4,999 for serving as a Speaker and Author with 好色先生. Dr. Muehlschlegel has a non-compensated relationship as a Member of Board of Directors with Neurocritical Care Society that is relevant to AAN interests or activities.